Clinical trial NCT02634489: EC905 Pharmacokinetic Profile Study
Official title: An Open-label, Parallel Group, Randomized, Two-way Crossover, Multiple Dose Study to Compare the Pharmacokinetic Profiles of Solifenacin Succinate and Tamsulosin HCl Following Co-administration of Single Entity Tablets and Administration of Three Different Dose Strengths of the Combination Tablet EC905
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Phase 1
Healthy
Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Keywords: Bladder outlet obstruction
Overactive bladder
Urinary incontinence
Omnic OCAS®
Vesicare®
Tamsulosin hydrochloride
Solifenacin succinate
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2015-12-18
Enrollment: 46
Sex: MALE
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.

Detailed description: There will be 3 dose cohorts of 15 subjects each. In Period 1, subjects will be randomized to either receive multiple doses of both tamsulosin HCl and solifenacin succinate as single entity tablets, or the combination tablet EC905. The alternate treatment will be provided in Period 2. The cohorts will be balanced for period effects and first-order carry over effects.

Eligibility criteria: Inclusion Criteria:

* Body Mass Index between 18.5 and 30.0 kg/m2.

Exclusion Criteria:

* Known or suspected hypersensitivity to tamsulosin HCl, solifenacin succinate, EC905 or any of the components of the formulations used.
* Any of the liver function tests above the upper limit of normal at repeated measurements.
* Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any other drug (excluding non-active hay fever).
* Subject is at risk of urinary retention based on medical history.
* A planned cataract surgery within 30 days after completion of the study.
* Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG and clinical laboratory tests.
* Abnormal pulse rate and/or blood pressure measurements at the pre-study visit as follows: pulse rate \<40 or \>90 bpm; mean systolic blood pressure \>160 mmHg; mean diastolic blood pressure \>100 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically).
* A marked baseline prolongation of QT/QTc interval after repeated measurements of 450 ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).
* Use of any prescribed or OTC (over-the counter) drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for occasional use of paracetamol (up to 3 g/day).
* Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
* Any use of drugs of abuse within 3 months prior to admission to the Clinical Unit.
* History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the Clinical Unit.
* History of drinking more than 21 units of alcohol per week (1 unit = 270 cc of beer or 40 cc of spirits or 1 glass of wine) within 3 months prior to admission to the Clinical Unit.
* Donation of blood or blood products within 3 months prior to admission to the Clinical Unit.
* Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.
* Participation in any clinical study within 3 months or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study, provided that the clinical study did not entail a biological compound with a long terminal half-life. An exception is (partly) participation in Astellas study 905-CL-071, provided a washout of at least 12 days is considered prior to re-enrolment.
* Employee of the Astellas Group or CRO involved in the study.

Primary outcomes:
measure: Pharmacokinetics (PK) of tamsulosin HCl and solifenacin succinate in plasma: AUCtau
timeFrame: Day 12
measure: PK of tamsulosin HCl and solifenacin succinate in plasma: Cmax
timeFrame: Day 12
Secondary outcomes:
measure: Safety profile assessed by adverse events, physical examination and vital signs, routine safety laboratory tests, and 12-lead ECG
timeFrame: Day 0 up to and including the post study visit (the PSV is scheduled between 7 to 14 days after (early) discharge on study day 13)
measure: PK profile Ctrough
timeFrame: Day 10, 11, 12, 13
measure: PK profile PTR
timeFrame: Day 12
measure: PK profile Tmax
timeFrame: Day 12
Other outcomes:
Locations:
city: Zuidlaren
country: Netherlands
facility: Site NL1
state: Drente
Study officials:
affiliation: Astellas Pharma Europe B.V.
name: Director Medical Sciences
role: STUDY_DIRECTOR
References: